While ADHD is often considered a childhood disorder, there is a significant number of adults in the United States (US) that are affected by the condition. Because untreated ADHD in adults can lead to poor clinical and functional outcomes, recognizing and diagnosing adult ADHD is of the utmost importance. In this session, expert faculty will discuss the best practices surrounding the application of long-acting stimulant formulations as well as appropriate pharmacotherapy to better treat and assess adult patients with ADHD.
This activity has been supported through an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.